BR112013028652A2 - anticorpos anti-fator de crescimento neuronal e métodos para preparação e utilização dos mesmos - Google Patents

anticorpos anti-fator de crescimento neuronal e métodos para preparação e utilização dos mesmos

Info

Publication number
BR112013028652A2
BR112013028652A2 BR112013028652A BR112013028652A BR112013028652A2 BR 112013028652 A2 BR112013028652 A2 BR 112013028652A2 BR 112013028652 A BR112013028652 A BR 112013028652A BR 112013028652 A BR112013028652 A BR 112013028652A BR 112013028652 A2 BR112013028652 A2 BR 112013028652A2
Authority
BR
Brazil
Prior art keywords
methods
growth factor
neuronal growth
antibodies
preparation
Prior art date
Application number
BR112013028652A
Other languages
English (en)
Other versions
BR112013028652A8 (pt
Inventor
David Gearing
Original Assignee
Nvip Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nvip Pty Ltd filed Critical Nvip Pty Ltd
Publication of BR112013028652A2 publication Critical patent/BR112013028652A2/pt
Publication of BR112013028652A8 publication Critical patent/BR112013028652A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/467—Igs with modifications in the FR-residues only
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Abstract

anticorpos anti-fator de crescimento neuronal e métodos para preparação e utilização dos mesmos é fornecido um método de preparação de um anticorpo adequado para uso em um equino. também são fornecidos anticorpos "equinizados" que se ligam especificamente ao fator de crescimento neuronal equino (ngf) e neutralizam a habilidade de ngf equino para se ligar ao receptor de ngf equino p75 trka. a invenção se estende aos ácidos nucléicos que o codificam e aos métodos de tratamento de dor e artrite em um equino usando os referidos anticorpos e/ou ácidos nucléicos.
BR112013028652A 2011-05-06 2012-05-08 Anticorpos anti-fator de crescimento neuronal e métodos para preparação e utilização dos mesmos BR112013028652A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161483491P 2011-05-06 2011-05-06
US201161531439P 2011-09-06 2011-09-06
PCT/GB2012/051004 WO2012153123A1 (en) 2011-05-06 2012-05-08 Anti-nerve growth factor antibodies and methods of preparing and using the same

Publications (2)

Publication Number Publication Date
BR112013028652A2 true BR112013028652A2 (pt) 2016-11-29
BR112013028652A8 BR112013028652A8 (pt) 2017-12-26

Family

ID=46168541

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013028652A BR112013028652A8 (pt) 2011-05-06 2012-05-08 Anticorpos anti-fator de crescimento neuronal e métodos para preparação e utilização dos mesmos

Country Status (14)

Country Link
US (2) US20140170136A1 (pt)
EP (2) EP3502136A1 (pt)
JP (2) JP6181043B2 (pt)
KR (1) KR101833465B1 (pt)
CN (1) CN103764677A (pt)
AU (1) AU2012252153B2 (pt)
BR (1) BR112013028652A8 (pt)
CA (1) CA2834983C (pt)
ES (1) ES2704007T3 (pt)
GB (1) GB2504888B (pt)
MY (1) MY160884A (pt)
RU (1) RU2640252C2 (pt)
SG (2) SG10201500957QA (pt)
WO (1) WO2012153123A1 (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
JP6190723B2 (ja) 2010-12-01 2017-08-30 アルダーバイオ ホールディングス エルエルシー 抗ｎｇｆ組成物およびその使用
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
ES2704007T3 (es) * 2011-05-06 2019-03-13 Nexvet Australia Pty Ltd Anticuerpos anti-factor de crecimiento nervioso y procedimientos de preparación y uso de los mismos
CN105829344B (zh) 2013-12-20 2021-12-07 英特维特国际股份有限公司 犬化鼠抗犬pd-1抗体
ES2853823T3 (es) 2014-09-30 2021-09-17 Intervet Int Bv Anticuerpos de PD-L1 que se unen a PD-L1 canino
CN104910274B (zh) * 2015-02-12 2018-05-04 北京华安科创生物技术有限公司 抗人神经生长因子的中和性单克隆抗体12c11及其杂交瘤细胞株
CN104774265B (zh) * 2015-02-12 2018-05-04 北京华安科创生物技术有限公司 抗人神经生长因子的中和性单克隆抗体11f1及其杂交瘤细胞株
CN107614683B (zh) * 2015-05-22 2020-12-22 安斯泰来制药株式会社 新型抗人NGF抗体Fab片段
US11091556B2 (en) 2015-12-18 2021-08-17 Intervet Inc. Caninized human antibodies to human IL-4R alpha
CA3071337A1 (en) * 2017-08-15 2019-02-21 Kindred Biosciences, Inc. Igg fc variants for veterinary use
GB2578867A (en) * 2018-10-09 2020-06-03 Genome Res Ltd Animal models and therapeutic molecules
AU2019250128A1 (en) 2018-10-15 2020-04-30 Avent Inc. Compositions, systems, kits, and methods for neural ablation
TW202306990A (zh) 2021-05-12 2023-02-16 大陸商江蘇恆瑞醫藥股份有限公司 特異性結合ｒａｎｋｌ和ｎｇｆ的抗原結合分子及其醫藥用途

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
AU634186B2 (en) 1988-11-11 1993-02-18 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
CA2022959C (en) * 1989-08-10 2001-03-20 Hiroaki Maeda Cat-mouse heterohybridoma and gene fragment coding for constant region of feline immunoglobulin
CA2110799A1 (en) 1991-06-14 1992-12-23 Arnold H. Horwitz Microbially-produced antibody fragments and their conjugates
ES2227512T3 (es) 1991-12-02 2005-04-01 Medical Research Council Produccion de anticuerpos contra auto-antigenos a partir de repertorios de segmentos de anticuerpos fijados en un fago.
SE9400088D0 (sv) 1994-01-14 1994-01-14 Kabi Pharmacia Ab Bacterial receptor structures
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
ATE448301T1 (de) 2000-09-08 2009-11-15 Univ Zuerich Sammlung von proteinen mit sich wiederholenden sequenzen (repeat proteins), die repetitive sequenzmodule enthalten
US20050053973A1 (en) 2001-04-26 2005-03-10 Avidia Research Institute Novel proteins with targeted binding
US20030157561A1 (en) 2001-11-19 2003-08-21 Kolkman Joost A. Combinatorial libraries of monomer domains
ITRM20030601A1 (it) * 2003-12-24 2005-06-25 Lay Line Genomics Spa Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti.
KR101504729B1 (ko) * 2004-04-07 2015-03-19 리나트 뉴로사이언스 코프. 신경성장인자 길항제의 투여에 의한 골암 통증 치료용 약학적 조성물
ITRM20050290A1 (it) * 2005-06-07 2006-12-08 Lay Line Genomics Spa Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato.
EP1929073A4 (en) 2005-09-27 2010-03-10 Amunix Inc PROTEIN MEDICAMENT AND ITS USE
WO2010027488A2 (en) * 2008-09-04 2010-03-11 Vet Therapeutics, Inc. Monoclonal antibodies
PT2448970E (pt) 2009-05-04 2014-10-20 Abbvie Res B V Anticorpos contra factor de crescimento nervoso (ngf) com estabilidade in vivo melhorada
CA2791560A1 (en) * 2010-03-04 2011-09-09 Vet Therapeutics Inc. Monoclonal antibodies directed to cd20
EP2542258A4 (en) * 2010-03-04 2013-08-21 Vet Therapeutics Inc MONOCLONAL ANTIBODIES DIRECTED AGAINST CD52
RS63063B1 (sr) * 2010-08-19 2022-04-29 Zoetis Belgium S A Anti-ngf antitela i njihova upotreba
ES2704007T3 (es) * 2011-05-06 2019-03-13 Nexvet Australia Pty Ltd Anticuerpos anti-factor de crecimiento nervioso y procedimientos de preparación y uso de los mismos

Also Published As

Publication number Publication date
JP2014519318A (ja) 2014-08-14
AU2012252153B2 (en) 2016-07-07
SG10201500957QA (en) 2015-04-29
SG194795A1 (en) 2013-12-30
CA2834983A1 (en) 2012-11-15
RU2013154307A (ru) 2015-06-20
GB2504888B (en) 2016-02-03
KR101833465B1 (ko) 2018-02-28
NZ617448A (en) 2015-01-30
RU2640252C2 (ru) 2017-12-27
MY160884A (en) 2017-03-31
US20140170136A1 (en) 2014-06-19
JP6526089B2 (ja) 2019-06-05
AU2012252153A8 (en) 2013-12-19
BR112013028652A8 (pt) 2017-12-26
AU2012252153A1 (en) 2013-11-14
EP2705056B1 (en) 2018-11-14
CA2834983C (en) 2020-11-17
WO2012153123A1 (en) 2012-11-15
GB201320050D0 (en) 2013-12-25
JP6181043B2 (ja) 2017-08-16
JP2017123870A (ja) 2017-07-20
US20190276525A1 (en) 2019-09-12
CN103764677A (zh) 2014-04-30
EP2705056A1 (en) 2014-03-12
ES2704007T3 (es) 2019-03-13
GB2504888A (en) 2014-02-12
EP3502136A1 (en) 2019-06-26
KR20140041532A (ko) 2014-04-04

Similar Documents

Publication Publication Date Title
BR112013028652A2 (pt) anticorpos anti-fator de crescimento neuronal e métodos para preparação e utilização dos mesmos
BR112013028654A2 (pt) anticorpos anti-fator de crescimento neuronal e métodos para preparação e utilização dos mesmos
BR112013028655A2 (pt) anticorpos anti-fator de crescimento neuronal e método para preparação e utilização dos mesmos
BR112018014585A2 (pt) receptores de antígeno quiméricos que direcionam o receptor do fator de crescimento epidérmico variante iii
BRPI1014522B8 (pt) anticorpo anti-actriib ou fragmento funcional, processo de produção dos mesmos, composição farmacêutica e usos
BR112014011331A2 (pt) anticorpos específicos para trop-2 e seus usos
CL2015002526A1 (es) Anticuerpos anti-ox40 y métodos de uso de los mismos.(divisional de 545-13).
EA201592154A1 (ru) Способ улучшения латентной гидравлической и/или пуццолановой активности материалов
BR112015019879A2 (pt) Composições de espécies de variantes moduladas de lisina e métodos para produção e uso das mesmas
BR112017011326A2 (pt) anticorpo, ácido nucleico, vetor, célula hospedeira, método para produzir o anticorpo, imunoconjugado, composição farmacêutica, usos do anticorpo, métodos para tratar ou retardar a progressão de distúrbio proliferativo celular e para intensificar a função imune
WO2015108998A3 (en) Cartilage targeting agents and their use
BR112017023646A2 (pt) proteínas agonistas de receptor de cd40 de cadeia simples
BR112012004823A8 (pt) Anticorpo ou fragmento de ligação de antígeno do mesmo, uso de um anticorpo ou um fragmento de ligação de antígeno do mesmo, e composição farmacêutica
BR112014020826A8 (pt) Anticorpo que se liga especificamente a um epítopo, ácido nucleico, vetor ou célula hospedeira, conjugado de fármaco – anticorpo, composição farmacêutica compreendendo o referido anticorpo, uso do mesmo, kit e método de preparação do conjugado
BR112016005526A2 (pt) anticorpos receptores de fator de crescimento anti-epidérmido modificado e métodos de uso dos mesmos
BR112013021134A8 (pt) Anticorpo isolado que se liga especificamente a ptk7 humano, seu uso, composição farmacêutica que o compreende, e ácido nucleico
MX2011000768A (es) Anticuerpos neutralizantes del virus anti-influenza a y usos de los mismos.
BRPI0715017A8 (pt) composições e métodos relativos aos anticorpos receptores de glucagon
EA201401065A1 (ru) Ang2-связывающие молекулы
CL2013002743A1 (es) Cristal de anticuerpo de igg anti-esclerostina; metodo de produccion; composicion que lo comprende; y su uso para tratar desordenes oseos.
TN2014000513A1 (en) Dual receptor antagonistic antigen-binding proteins and uses thereof
BR112017022255A2 (pt) anticorpo humanizado ou humano isolado, molécula de ácido nucleico isolada, vetor, célula hospedeira, método para produzir um anticorpo, e composição farmacêutica
BRPI0919236A8 (pt) Terapêutica e vacinas de combinação de gas
BR112018006006A2 (pt) receptores de antígeno, cadeias peptídicas, células recombinantes, métodos para produzir uma célula que expressa um receptor de antígeno e para o tratamento de uma doença, ácidos nucleicos e composição farmacêutica
CL2015001230A1 (es) Método de selección de proteínas ligantes de antígeno her3 humano y her4 humano; proteína ligante; anticuerpo ligante de her3 y her4; ácido nucleico que lo codifica; célula huésped; método de producción; formulación farmacéutica que lo comprende; uso para tratar el cáncer; y epítopos.

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved

Owner name: NVIP PTY LTD (AU)

B25A Requested transfer of rights approved

Owner name: NEXVET AUSTRALIA PTY LTD (AU)

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements